Ozempic vs Wegovy: The Same Drug With Very Different Rules

Chemically, yes — both are semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. Semaglutide mimics GLP-1 (glucagon-like peptide-1), a natural gut hormone that signals fullness to the brain, slows stomach emptying, and helps the pancreas release insulin when blood sugar rises. The molecule in an Ozempic pen and a Wegovy pen is identical.

What differs is everything around the molecule. Ozempic was FDA-approved in 2017 for type 2 diabetes, with maximum dosing of 2 mg weekly. Wegovy was approved in 2021 specifically for chronic weight management, with a higher maximum dose of 2.4 mg weekly, after trials showed the higher dose produced substantially more weight loss. In 2024, Wegovy added a second indication: reducing cardiovascular risk in people with heart disease and obesity.

This 'same drug, two labels' situation isn't unusual in medicine, and it matters practically: your diagnosis determines which label applies to you, and the label determines what insurance will pay for. If you're comparing semaglutide against the other major GLP-1, tirzepatide, start with our [tirzepatide vs semaglutide comparison](/blog/tirzepatide-vs-semaglutide-comparison-2026).

Wegovy escalates to a higher maximum dose — that's the core clinical difference. Both medications start low and step up gradually to manage side effects, but they top out at different places.

Ozempic titration: 0.25 mg weekly for 4 weeks (starter, not therapeutic), then 0.5 mg, with options to increase to 1 mg and a maximum of 2 mg weekly based on blood sugar control.

Wegovy titration: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, stepping up roughly every 4 weeks. The 2.4 mg maintenance dose is the one validated for weight loss in the STEP trial program.

The dose gap explains the results gap. In STEP 1 (NEJM 2021), semaglutide 2.4 mg produced 14.9% average weight loss over 68 weeks. At Ozempic's diabetes doses, weight loss is real but more modest — typically in the 4–7% range in the SUSTAIN diabetes trials. Dose-response is also why some people who 'didn't lose much on Ozempic' do meaningfully better after switching to Wegovy's full 2.4 mg.

Side effects scale with dose too — nausea and digestive issues are more common during escalation to 2.4 mg, which is why the slow ramp matters.

Insurance — not pharmacology — is what really decides between Ozempic and Wegovy for most people.

If you have type 2 diabetes, Ozempic is usually the covered path. Most commercial plans and Medicare Part D cover GLP-1s for diabetes, often with prior authorization confirming the diagnosis.

If you don't have diabetes, Ozempic is technically off-label for weight loss, and insurers have tightened prior authorizations significantly — many now require documented diabetes for Ozempic claims. Wegovy is the on-label route, but weight-management coverage varies enormously: some commercial plans cover it fully, others exclude weight-loss drugs entirely. Medicare historically couldn't cover weight-loss medications, though Wegovy's cardiovascular indication opened a door — Medicare plans can now cover it for patients with established heart disease and obesity following the SELECT trial results.

Paying cash? Novo Nordisk's NovoCare pharmacy offers Wegovy directly at reduced cash prices, and manufacturer savings cards cut costs for the commercially insured. Current prices, eligibility rules, and stacking strategies change often — our [GLP-1 savings card guide](/blog/glp1-savings-cards-2026-complete-guide) keeps the full playbook.

Practical tip: have your clinician's office run the prior authorization for both labels before assuming anything. Coverage denials are frequently overturned on appeal with documentation of BMI, comorbidities, and prior weight-loss attempts.

The side-effect profile is the same — it's one molecule — but intensity tracks with dose. The most common effects for both: nausea, constipation, diarrhea, fatigue, and burping, concentrated during dose escalation and usually fading as your body adapts. Because Wegovy reaches 2.4 mg, users are somewhat more likely to experience GI effects at the top of titration; the fix is usually slower escalation, not abandoning treatment. Our guides to [managing GLP-1 nausea](/blog/glp1-nausea-why-it-happens-and-how-to-stop-it) and [fixing GLP-1 constipation](/blog/glp1-constipation-what-actually-works) cover the practical strategies.

Both carry the same boxed warning about thyroid C-cell tumors observed in rodents — not demonstrated in humans — and the same precautions around pancreatitis, gallbladder disease, and use in pregnancy. People with personal or family history of medullary thyroid carcinoma or MEN2 syndrome shouldn't use either; the full evidence picture is in our [GLP-1 thyroid safety review](/blog/glp-1-and-thyroid-safety-what-the-data-shows).

One safety advantage now sits on Wegovy's label: the SELECT trial (NEJM 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events — heart attack, stroke, cardiovascular death — by 20% in people with existing heart disease and overweight or obesity, without diabetes. That earned Wegovy its cardiovascular indication, a meaningful consideration if heart disease runs in your family.

Let your diagnosis and coverage decide, because the molecule won't.

Choose Ozempic if you have type 2 diabetes. It's the on-label option, insurance coverage is far more reliable, and blood sugar control is its designed purpose — with significant weight loss as a well-documented effect.

Choose Wegovy if your goal is weight management without diabetes. It's the on-label route, reaches the dose with the strongest weight-loss evidence, and adds the cardiovascular indication if you have established heart disease.

Consider the wider field too. Tirzepatide (Zepbound for weight, Mounjaro for diabetes) outperformed semaglutide head-to-head in SURMOUNT-5 — 20.2% vs 13.7% average weight loss — and may be preferred if your insurance covers it. For menopausal women, the calculus has extra layers (muscle, bone, hormone interactions) that we cover in [whether GLP-1s work during menopause](/blog/do-glp1s-work-during-menopause-what-studies-show).

What you shouldn't do is chase whichever name is trending. 'Ozempic' became cultural shorthand, but if you don't have diabetes, asking your doctor for Wegovy by name will usually get you to the same molecule with fewer insurance battles and a higher therapeutic dose.

Switching between Ozempic and Wegovy is medically straightforward since the molecule is identical — clinicians map you to the nearest equivalent dose and continue titration under the new label. The friction is administrative: a new prescription, a new prior authorization, and occasionally a pharmacy stock hunt. Keep dosing records; gaps during a switch can mean restarting at lower doses and re-experiencing escalation side effects.

Compounded semaglutide is the budget path many people ask about. During the FDA-declared shortage, compounding pharmacies could legally produce semaglutide copies; with the shortage resolved, the legal window for mass compounding has closed and the FDA has moved against large-scale compounders. Quality varies dramatically — compounded versions aren't FDA-reviewed for purity or potency, and dosing errors with vial-and-syringe formats caused documented overdoses. If cost is the obstacle, exhaust the legitimate discounts first: manufacturer savings cards, NovoCare direct pricing, and appeal letters.

Wherever you land, the decision deserves a real conversation with a prescriber who knows your history — and ongoing support for the months that follow, because titration questions, plateaus, and side-effect management are where outcomes are actually won.